Stoke Therapeutics (NASDAQ:STOK) Stock Rating Lowered by Wall Street Zen

Stoke Therapeutics (NASDAQ:STOK) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Saturday.

Several other brokerages have also recently issued reports on STOK. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Stoke Therapeutics in a report on Monday, December 29th. HC Wainwright upped their target price on Stoke Therapeutics from $35.00 to $50.00 and gave the company a “buy” rating in a report on Monday, December 15th. UBS Group set a $50.00 price target on Stoke Therapeutics in a research report on Monday, December 15th. Chardan Capital reaffirmed a “buy” rating and set a $35.00 price target on shares of Stoke Therapeutics in a research note on Wednesday. Finally, Wedbush increased their price objective on shares of Stoke Therapeutics from $36.00 to $38.00 and gave the company an “outperform” rating in a research note on Tuesday. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $41.83.

Stoke Therapeutics Trading Up 1.0%

STOK stock opened at $33.51 on Friday. The firm has a 50 day moving average of $32.61 and a 200-day moving average of $30.02. Stoke Therapeutics has a 12-month low of $5.35 and a 12-month high of $40.22. The company has a market cap of $1.98 billion, a price-to-earnings ratio of 50.01 and a beta of 1.07.

Insider Buying and Selling

In related news, CFO Thomas Leggett sold 2,382 shares of the stock in a transaction on Wednesday, March 18th. The stock was sold at an average price of $31.34, for a total value of $74,651.88. Following the transaction, the chief financial officer directly owned 10,172 shares of the company’s stock, valued at approximately $318,790.48. This trade represents a 18.97% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, General Counsel Jonathan Allan sold 4,628 shares of Stoke Therapeutics stock in a transaction on Wednesday, March 18th. The shares were sold at an average price of $31.34, for a total value of $145,041.52. Following the completion of the transaction, the general counsel owned 28,836 shares in the company, valued at $903,720.24. The trade was a 13.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 69,699 shares of company stock worth $2,526,714 over the last 90 days. Company insiders own 9.50% of the company’s stock.

Hedge Funds Weigh In On Stoke Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of STOK. Invesco Ltd. grew its holdings in shares of Stoke Therapeutics by 24.7% during the 4th quarter. Invesco Ltd. now owns 259,543 shares of the company’s stock worth $8,238,000 after purchasing an additional 51,468 shares during the period. NewEdge Advisors LLC purchased a new position in Stoke Therapeutics in the fourth quarter valued at approximately $330,000. Tudor Investment Corp ET AL acquired a new position in Stoke Therapeutics during the fourth quarter valued at approximately $613,000. Readystate Asset Management LP purchased a new stake in Stoke Therapeutics during the fourth quarter worth approximately $922,000. Finally, RTW Investments LP grew its stake in Stoke Therapeutics by 8.3% during the fourth quarter. RTW Investments LP now owns 5,546,856 shares of the company’s stock worth $176,057,000 after buying an additional 423,331 shares during the period.

Stoke Therapeutics News Roundup

Here are the key news stories impacting Stoke Therapeutics this week:

• Positive Sentiment: Canaccord raised its price target sharply to $60 and assigned a Buy, giving STOK a meaningful upside projection versus recent levels — a clear catalyst for buying interest. Canaccord raises STOK price target to $60 (Benzinga)
• Positive Sentiment: Other analysts reiterated/raised Buy views and targets (BTIG reaffirmed Buy with a $39 target; Wedbush pushed its target to $38; Needham published a bullish outlook), adding breadth to the bullish narrative and likely attracting momentum and institutional buyers. BTIG reaffirmation (Benzinga) Wedbush boosts price target to $38 (AmericanBankingNews) Needham bullish outlook (AmericanBankingNews)
• Positive Sentiment: Coverage of Stoke’s STK‑001 program emphasizes potential beyond seizure reduction (aiming to restore developmental loss in Dravet syndrome), supporting longer‑term upside expectations if clinical data meet endpoints. FierceBiotech: Stoke aims to restore developmental loss in Dravet syndrome
• Neutral Sentiment: Analysis pieces reviewed a recent sharp pullback and what triggered it—useful context for traders but not a new company catalyst. Kalkine: What triggered the sudden drop?
• Neutral Sentiment: Technical/volume note — today’s volume is well above average and the stock is trading above both its 50‑ and 200‑day SMAs, indicating higher investor interest; this can amplify moves in either direction.
• Negative Sentiment: Significant insider selling: multiple executives (including the CFO, general counsel and senior insiders such as Barry Ticho) disclosed sizable sales across March 17–19, which can weigh on sentiment and prompt investor caution despite analyst optimism. Representative SEC filings: SEC Form 4 (Jonathan Allan) SEC Form 4 (Barry Ticho)

About Stoke Therapeutics

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.